Orphazyme As Stock Current Ratio

ORPHA Stock  DKK 1,190  10.00  0.83%   
Orphazyme AS fundamentals help investors to digest information that contributes to Orphazyme's financial success or failures. It also enables traders to predict the movement of Orphazyme Stock. The fundamental analysis module provides a way to measure Orphazyme's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Orphazyme stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Orphazyme Current Ratio Analysis

Orphazyme's Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.

Current Ratio

 = 

Current Asset

Current Liabilities

More About Current Ratio | All Equity Analysis

Current Orphazyme Current Ratio

    
  4.70 X  
Most of Orphazyme's fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Orphazyme AS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
Competition

In accordance with the recently published financial statements, Orphazyme AS has a Current Ratio of 4.7 times. This is 61.51% higher than that of the Biotechnology sector and 32.86% lower than that of the Health Care industry. The current ratio for all Denmark stocks is 117.59% lower than that of the firm.

Orphazyme Current Ratio Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Orphazyme's direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Orphazyme could also be used in its relative valuation, which is a method of valuing Orphazyme by comparing valuation metrics of similar companies.
Orphazyme is currently under evaluation in current ratio category among related companies.

Orphazyme Fundamentals

About Orphazyme Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Orphazyme AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Orphazyme using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Orphazyme AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Orphazyme AS, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark. Orphazyme is traded on Copenhagen Stock Exchange in Denmark.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Orphazyme Piotroski F Score and Orphazyme Altman Z Score analysis.
Note that the Orphazyme AS information on this page should be used as a complementary analysis to other Orphazyme's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.

Complementary Tools for Orphazyme Stock analysis

When running Orphazyme's price analysis, check to measure Orphazyme's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Orphazyme is operating at the current time. Most of Orphazyme's value examination focuses on studying past and present price action to predict the probability of Orphazyme's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Orphazyme's price. Additionally, you may evaluate how the addition of Orphazyme to your portfolios can decrease your overall portfolio volatility.
Stocks Directory
Find actively traded stocks across global markets
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Please note, there is a significant difference between Orphazyme's value and its price as these two are different measures arrived at by different means. Investors typically determine if Orphazyme is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Orphazyme's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.